News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
AstraZeneca PLC Drug Zibotentan Fails in Prostate Cancer Trial
September 27, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Sept 27 (Reuters) - AstraZeneca's (AZN.L) experimental prostate cancer pill zibotentan failed to improve survival in a late-stage clinical trial, dealing a fresh blow to the company's oncology pipeline.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
AstraZeneca
MORE ON THIS TOPIC
Duchenne muscular dystrophy
Entrada crashes as Duchenne therapy comes in ‘below expectations’ in early study
May 7, 2026
·
2 min read
·
Tristan Manalac
Insights
Fibrosis, IPF and the search for better therapies
May 7, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Business
CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026
May 6, 2026
·
1 min read
·
Gabrielle Masson
Immunology and inflammation
Viridian turns green again as new Phase 3 data vindicate thyroid eye disease drug
May 6, 2026
·
1 min read
·
Tristan Manalac
